Search

Cognitive impairment in patients with type 2 diabetes mellitus (DM-2) currently attracts a lot of attention due to their impact on quality of life and the effectiveness of treatment. The aim of research is to find the most effective medication which influences the cognitive functions positively. The research included 120 patients with average age of 61.22 ± 8.6 and average DM-2 duration of 10.84 ± 8.2 years. Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA test), Trail Making Test (TMT), Parts A and B, Hospital Anxiety and Depression Scale (HADS), and The Short Form-36 (SF-36) were used. It was revealed that patients with DM type 2 had cognitive dysfunction generally presented by mild cognitive impairment. Patients with DM-2 have an early manifestation of cognitive impairment. After the initial estimation of indicators, all the patients were taking standardized extract Ginkgo biloba (EGb 761®) in the dose 240 mg a day for 6 months. Estimation of all the indicators after 3 and 6 months of treatment showed significant cognitive improvement. By matching the available experimental and clinical data, we can conclude that in the setting of DM-2 EGb 761®, by producing a positive effect towards various factors which results from insulin resistance of the brain, improves functions of the brain, which manifests in improvement of main QoL indicators in DM-2. [ABSTRACT FROM AUTHOR]